Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
CRVO Stock Chart & Stats
$7.28
-$0.11(-4.76%)
At close: 4:00 PM EST
$7.28
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$1.92 - $16.94
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$67.36M
Enterprise Value$57.92M
Total Cash (Recent Filing)$27.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding9,252,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue179.57
Enterprise Value/Gross Profit179.57
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$22.75Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionUse of a refined plasma biomarker cutoff to enroll patients with low likelihood of Alzheimer pathology is designed to enrich for 'pure' DLB patients and improve the likelihood of detecting drug benefit in Phase 3.
Clinical EfficacyPhase 2b data demonstrated over seventy-five percent slowing of cognitive decline on CDR‑SB in a biomarker-selected DLB subgroup, indicating a potentially meaningful treatment effect.
Regulatory PathwayFDA alignment on a single randomized pivotal Phase 3 trial for neflamapimod establishes a clear regulatory path that could support eventual approval in dementia with Lewy bodies.
Bears Say
Assay ReliabilityPrevious inaccuracies in assay conversion that affected patient selection in earlier trials raise concerns about biomarker assay reliability and the risk of misclassification in future studies.
Dose And Manufacturing RiskDose determination tied to the bioavailability of new drug batches creates risk that formulation or manufacturing variability could delay trial initiation or complicate dosing decisions.
Financing RequirementThe company needs to raise seventy to ninety million dollars to fully fund the planned Phase 3 trial, creating potential dilution or dependence on external financing.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.92 and its highest was $16.94 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $67.36M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is May 19, 2026 which is in 121 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 10, 2025. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.657 by -$0.183.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CervoMed have?
CervoMed has 9,252,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.657. Following the earnings report the stock price went down -0.289%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.75 (212.50% Upside)
$22.75 (212.50% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $737.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 23.3%
Last 30 Days ▲ 23.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-71.42%
Trailing 12-Months
Asset Growth
-28.41%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$22.75
▲(212.50% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
44.10% Insiders
3.95% Mutual Funds
0.59% Other Institutional Investors
47.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---